A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Filibuvir Plus Pegylated Interferon Alfa-2a And Ribavirin In Treatment-Naive, HCV Genotype 1 Infected Subjects.
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Filibuvir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms FITNESS
- Sponsors Pfizer
- 03 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov..
- 27 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.